Skip to main content

Advertisement

Table 1 Characteristics of included studies in the network of evidence

From: Relative efficacy of interventions in the treatment of second-line non-small cell lung cancer: a systematic review and network meta-analysis

Study Restriction Interventions N
Aerts et al. (2013) [49] (NVALT-10) Nonsquamous histology Erlotinib (150 mg) 73
Erlotinib (150 mg) + pemetrexed (500 mg/m2) 82
Aerts et al. (2013) [49] (NVALT-10) Squamous histology Erlotinib (150 mg) 42
Docetaxel (75 mg/m2) + erlotinib (150 mg) 34
Auliac et al. (2014) [50] EGFR mutation negative or unknown Docetaxel (75 mg/m2) 74
Docetaxel (75 mg/m2) + erlotinib (150 mg) 73
Borghaei et al. (2015) [39] (CheckMate 057) Not restricted Docetaxel (75 mg/m2) 224
Nivolumab 3 mg/kg 231
Brahmer et al. (2015)e [40] (CheckMate 017) Not restricted Docetaxel (75 mg/m2) 108
Nivolumab 3 mg/kg 117
Camps et al. (2006) [51] Not restricted Docetaxel (75 mg/m2) 129
Frequent low-dose docetaxel 125
Fossella (2000) [52] Not restricted Docetaxel (75 mg/m2) 125
Docetaxel (100 mg/m2) 125
Garassino et al. (2013) [53] (TAILOR) EGFR mutation negative Docetaxel (75 mg/m2) 110
Erlotinib 150 mg 109
Garon et al. (2014) [54] (REVEL) Not restricted Docetaxel (75 mg/m2) 618
Docetaxel (75 mg/m2) + ramucirumab (10 mg/kg) 622
Gervais et al. (2005) [55] Not restricted Docetaxel (75 mg/m2) 62
Frequent low-dose docetaxel 63
Gridelli et al. (2004) [56] (DISTAL 01) Not restricted Docetaxel (75 mg/m2) 110
Frequent low-dose docetaxel 110
Han et al. (2011) [57] Not restricted Docetaxel (75 mg/m2) 40
Pemetrexed (500 mg/m2) 44
Hanna et al. (2004) [58]; Scagliotti et al. (2009) [37] Not restricted Docetaxel (75 mg/m2) 288
Pemetrexed (500 mg/m2) 283
Hanna et al. (2013) [59] (LUME-Lung 2) Not restricted Pemetrexed (500 mg/m2) 360
Pemetrexed (500 mg/m2) + nintedanib (200 mg) 353
Hosomi et al. (2015) [60] Asian population Docetaxel (60 mg/m2) 81
Docetaxel (60 mg/m2) + ramucirumab (10 mg/kg) 76
Juan et al. (2015) [61] Not restricted Erlotinib (150 mg) 35
Docetaxel (75 mg/m2) + erlotinib (150 mg) 33
Karampeazis et al. (2013) [62] (NCT00440414) Not restricted Erlotinib (150 mg) 39
Pemetrexed (500 mg/m2) 36
Katakami et al. (2014) [63] / Urata et al. (2016) [35] Asian population Erlotinib (150 mg) 252
Gefitinib (250 mg) 250
Kawaguchi et al. (2014) [46] (DELTA) Asian population Erlotinib (150 mg) 150
Docetaxel (60 mg/m2) 151
Kim et al. (2008) [64] Not restricted Docetaxel (75 mg/m2) 710
Gefitinib (250 mg) 723
Kim et al. (2014) [65] Asian population Pemetrexed (500 mg/m2) 45
Gefitinib (250 mg) 43
Lee et al. (2013) [66] Not restricted Erlotinib (150 mg) 82
Pemetrexed (500 mg/m2) 77
Erlotinib (150 mg) + pemetrexed (500 mg/m2) 75
Nishino et al. (2015) [67] Nonsquamous histology
Asian population
Docetaxel (60 mg/m2) + bevacizumab (15 mg/kg) 45
S-1 (40 mg/m2) + bevacizumab (15 mg/kg) 45
Quoix et al. (2004) [68] Not restricted Docetaxel (75 mg/m2) 93
Docetaxel (100 mg/m2) 89
Reck et al. (2014) [38] (LUME-Lung 1) Not restricted Docetaxel (75 mg/m2) 615
Docetaxel (75 mg/m2) + nintedanib (200 mg) 598
Schuette et al. (2005) [69] Not restricted Docetaxel (75 mg/m2) 103
Frequent low-dose docetaxel 105
Shepherd et al. (2000) [70] Not restricted Docetaxel (75 mg/m2) 55
Best supportive care 49
Sun et al. (2012) [34] (KCSG-LU08–01) Adenocarcinoma histology
Asian population
Pemetrexed (500 mg/m2) 67
Gefitinib (250 mg) 68
Sun et al. (2013) [71] (JMID) Asian population Docetaxel (75 mg/m2) 98
Pemetrexed (500 mg/m2) 104
Takeda et al. (2015;2016) [72, 73] Nonsquamous histology
Progressed after treatment with bevacizumab plus a platinum-based doublet.
Asian population
Docetaxel (60 mg/m2) 50
Docetaxel (60 mg/m2) + bevacizumab (15 mg/kg) 50
Zhou et al. (2013;2014) [74, 75] Nonsquamous histology
EGFR mutation negative
Asian population
Pemetrexed (500 mg/m2) 76
Gefitinib (250 mg) 81